Sphingosine kinase type 1 inhibitors
US-9388121-B2 · Jul 12, 2016 · US
US10456370B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10456370-B2 |
| Application number | US-201816199337-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 26, 2018 |
| Priority date | Apr 29, 2008 |
| Publication date | Oct 29, 2019 |
| Grant date | Oct 29, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are inhibitors of sphingosine kinase Type I and their use in the treatment of asthma, among other indications and diseases.
Opening claim text (preview).
What is claimed is: 1. A method for treating asthma in a patient, comprising: administering to a patient in need of treatment for asthma a compound having the formula 2. The method of claim 1 , wherein the administering step comprises administering to the patient the compound having the formula 3. The method of claim 2 , wherein the administering step comprises administering to the patient 4. A method for treating asthma in a patient, comprising: administering to a patient in need of treatment for asthma a compound having the formula wherein R comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. 5. The method of claim 4 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. 6. The method of claim 5 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring. 7. The method of claim 6 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, or a branched carbon chain comprising one or more heteroatoms. 8. The method of claim 7 , wherein R is a straight carbon chain or a branched carbon chain. 9. The method of claim 8 , wherein R is a straight carbon chain.
having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton · CPC title
having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title
with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms · CPC title
Antiasthmatics · CPC title
and containing six-membered aromatic rings · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.